Navigation Links
Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
Date:12/5/2007

CAMBRIDGE, Mass, Dec. 5 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myelogenous leukemia (AML) who are unlikely to benefit from standard induction therapy. Data from this study are expected to provide substantial evidence for expanding the current product label into adult AML.

"We are very pleased to have reached this milestone and to have done so in a timeframe that we expect will allow us to present preliminary data at ASCO next spring," stated Mark Enyedy, president of Genzyme Oncology. "The completion of patient enrollment in this clinical study is another important step in our plan to broaden the Clolar label to benefit a larger patient population and address multiple lines of adult AML."

Genzyme has held preliminary discussions with the U.S. Food and Drug Administration in advance of submitting a supplemental new drug application (sNDA) for clofarabine as an initial treatment in older adults with AML. The company expects to file this sNDA in the second half of next year.

Significant Unmet Medical Need

The clinical trial, known as CLASSIC II, is designed to address a high unmet medical need among older AML patients who currently have limited treatment options. According to the American Cancer Society, each year approximately 6,500 people over the age of 60 are diagnosed with AML in the U.S. The median survival for those receiving therapy can vary from one to thirteen months, and the five-year survival rate over the past three decades remains at less than 15 percent. Old
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
9. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
10. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
(Date:7/10/2014)... , July 10, 2014 Integrated Silicon ... in advanced memory and analog IC solutions, today announced ... Thursday, July 24, 2014, at 7:00 a.m. Pacific Time ... results for the fiscal 2014 third quarter ended June ... via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific time ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... , HARRISBURG, Pa., Aug. 20 Department of Environmental ... number of West Nile Virus cases has dropped, the threat still ... and make every effort to control mosquitoes and reduce the threat ... number of West Nile cases has substantially decreased in recent years ...
... , , , , ... Stemedica Cell Technologies , Inc. USA, a ... New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") ... mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke. ...
Cached Medicine Technology:DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 2DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat 3Stemedica Requests Pre-IND Meeting With FDA 2
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of her ... use of his left side. Eating became a difficult task for ... like them enjoy eating again,” said an inventor, from Fayetteville, N.C. ... HALL PLATE (P C H PLATE). , The PATRICIA CAROL HALL ... eat for individuals who suffer from stroke, experience tremors or loss ...
(Date:7/12/2014)... With prom shopping reaching its final ... is ready to showcase its new and trendy apparels. ... evening dresses in its online shop. Additionally, it is ... these elegant gowns. According to the company’s sales manager, ... 26, 2014. , He says, “Now, worldwide clients ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major Developed ... PCCs and Recombinant Products to Drive Market,” which ... in the US, UK, France, Germany, Italy, Spain, ... of market size for 2013, along with market ... that are being treated using the five major ...
(Date:7/12/2014)... Utah Valley Entrepreneurial Forum Top 25 ... being bestowed to companies in revenue, and pre-revenue startups. ... with recognition for new ideas as well as companies ... , 25 Under 5 highlights outstanding Utah entrepreneurs and ... 5 years old. Award recipients were recognized at their ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2
... new funding from the Bill & Melinda Gates Foundation to ... help agency expand services in 11 new countries, ... world,s largest microfinance organizations, today,announced it has received a $24.2 ... will help Opportunity International,s,subsidiary, the Micro Insurance Agency, greatly expand ...
... Quarter 2008 Sees 52 Percent Increase in Sales from Same ... ... Greenway Medical Technologies,Inc., a leading provider of integrated electronic health records ... its second quarter of fiscal 2008, ending,December 31, 2007, were up ...
... announced it will host a webcast and conference call at 10 am,ET on Friday, ... 2007, which ended December 31. Financial,results are scheduled for release after the market closes ... Robert Holster, Chairman and CEO ... Walter Hosp, SVP ...
... more likely to remain depressed than older men, according to ... the February Archives of General Psychiatry. , The Yale ... while depressed than older men, indicating that women live longer ... likelihood of women becoming depressed and remaining depressed, collectively contribute ...
... constructed with soft lithography, should boost research in which ... screen new pharmaceuticals for potential treatment of parasitic infections ... The tools -- an artificial soil device and a ... easily in a human hand -- are detailed in ...
... Alienation Awareness,Organization (PAAO) is beginning the New Year by ... Parental Alienation Awareness Day., Because most people do ... alienation awareness was put forth to help raise,awareness and ... PAAO is to help the public and professionals become,aware ...
Cached Medicine News:Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4Health News:HMS Holdings Corp. Hosts Fourth Quarter and Full Year 2007 Financial Teleconference and Presentation 2Health News:Older women more susceptible to depression than older men 2Health News:New devices to boost nematode research on neurons and drugs 2Health News:New devices to boost nematode research on neurons and drugs 3Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: